Kymera Historical Financial Ratios

KYMR Stock

USD 40.45 1.05 2.66%

Kymera Therapeutics is lately reporting on over 94 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 82.34 will help investors to properly organize and evaluate Kymera Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

About Kymera Financial Ratios Analysis

Kymera TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Kymera Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Kymera financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Kymera Therapeutics history.

Kymera Therapeutics Financial Ratios Chart

At this time, Kymera Therapeutics' Capex To Revenue is relatively stable compared to the past year. As of 01/31/2025, Income Quality is likely to grow to 0.66, while Book Value Per Share is likely to drop 5.25.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Payables Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Kymera Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Kymera Therapeutics sales, a figure that is much harder to manipulate than other Kymera Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Kymera Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.At this time, Kymera Therapeutics' Capex To Revenue is relatively stable compared to the past year. As of 01/31/2025, Income Quality is likely to grow to 0.66, while Book Value Per Share is likely to drop 5.25.

	2022	2023	2024	2025 (projected)
Current Ratio	8.84	4.73	4.26	4.47
Net Debt To EBITDA	0.34	0.18	0.2	0.19

Current Ratio Net Debt To E B I T D A

Kymera Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.97	-0.59	-0.9	0.55	0.2	0.04	-0.97	1.0	0.31	-0.93	-0.87	0.98	0.84	-0.75	-0.38	-0.83	-0.56	-0.88	0.39	-0.55	0.95	0.21	0.99	-0.57	-0.93
Ptb Ratio	-0.97		0.54	0.86	-0.48	-0.17	-0.19	1.0	-0.97	-0.27	0.93	0.83	-0.97	-0.8	0.7	0.34	0.83	0.74	0.94	-0.31	0.73	-0.99	-0.3	-0.97	0.75	0.97
Days Sales Outstanding	-0.59	0.54		0.26	-0.68	-0.33	0.62	0.54	-0.59	-0.45	0.32	0.73	-0.66	-0.8	0.93	0.9	0.19	0.3	0.36	-0.92	0.31	-0.6	0.02	-0.67	0.3	0.66
Book Value Per Share	-0.9	0.86	0.26		-0.16	0.18	-0.19	0.86	-0.89	0.09	0.98	0.56	-0.84	-0.51	0.53	0.17	0.98	0.52	0.9	0.0	0.5	-0.83	-0.48	-0.84	0.52	0.77
Free Cash Flow Yield	0.55	-0.48	-0.68	-0.16		0.86	-0.18	-0.48	0.55	0.91	-0.24	-0.88	0.59	0.87	-0.5	-0.32	0.0	-0.13	-0.18	0.75	-0.12	0.46	-0.57	0.63	-0.13	-0.59
Operating Cash Flow Per Share	0.2	-0.17	-0.33	0.18	0.86		0.02	-0.17	0.2	0.99	0.07	-0.63	0.2	0.59	-0.08	0.06	0.33	0.1	0.12	0.54	0.11	0.11	-0.86	0.27	0.1	-0.23
Capex To Depreciation	0.04	-0.19	0.62	-0.19	-0.18	0.02		-0.19	0.04	-0.06	-0.24	0.06	0.02	-0.16	0.54	0.77	-0.23	-0.45	-0.28	-0.71	-0.44	0.14	0.12	0.0	-0.45	-0.11
Pb Ratio	-0.97	1.0	0.54	0.86	-0.48	-0.17	-0.19		-0.97	-0.27	0.93	0.83	-0.97	-0.8	0.7	0.34	0.83	0.74	0.94	-0.31	0.73	-0.99	-0.3	-0.97	0.75	0.97
Ev To Sales	1.0	-0.97	-0.59	-0.89	0.55	0.2	0.04	-0.97		0.31	-0.93	-0.87	0.98	0.84	-0.75	-0.38	-0.83	-0.56	-0.88	0.39	-0.55	0.95	0.21	0.99	-0.57	-0.93
Free Cash Flow Per Share	0.31	-0.27	-0.45	0.09	0.91	0.99	-0.06	-0.27	0.31		-0.03	-0.72	0.31	0.69	-0.22	-0.07	0.24	0.04	0.02	0.64	0.05	0.22	-0.81	0.39	0.04	-0.34
Roic	-0.93	0.93	0.32	0.98	-0.24	0.07	-0.24	0.93	-0.93	-0.03		0.66	-0.89	-0.61	0.58	0.2	0.96	0.62	0.96	-0.09	0.6	-0.9	-0.43	-0.89	0.62	0.84
Inventory Turnover	-0.87	0.83	0.73	0.56	-0.88	-0.63	0.06	0.83	-0.87	-0.72	0.66		-0.88	-0.98	0.71	0.4	0.44	0.43	0.62	-0.67	0.42	-0.81	0.22	-0.91	0.43	0.87
Net Income Per Share	0.98	-0.97	-0.66	-0.84	0.59	0.2	0.02	-0.97	0.98	0.31	-0.89	-0.88		0.87	-0.78	-0.46	-0.78	-0.64	-0.86	0.45	-0.63	0.96	0.25	0.99	-0.64	-0.97
Days Of Inventory On Hand	0.84	-0.8	-0.8	-0.51	0.87	0.59	-0.16	-0.8	0.84	0.69	-0.61	-0.98	0.87		-0.77	-0.5	-0.4	-0.42	-0.59	0.75	-0.41	0.79	-0.19	0.89	-0.42	-0.85
Payables Turnover	-0.75	0.7	0.93	0.53	-0.5	-0.08	0.54	0.7	-0.75	-0.22	0.58	0.71	-0.78	-0.77		0.9	0.5	0.42	0.61	-0.77	0.42	-0.75	-0.25	-0.79	0.43	0.76
Capex To Revenue	-0.38	0.34	0.9	0.17	-0.32	0.06	0.77	0.34	-0.38	-0.07	0.2	0.4	-0.46	-0.5	0.9		0.17	0.23	0.27	-0.79	0.24	-0.43	-0.25	-0.44	0.23	0.45
Cash Per Share	-0.83	0.83	0.19	0.98	0.0	0.33	-0.23	0.83	-0.83	0.24	0.96	0.44	-0.78	-0.4	0.5	0.17		0.58	0.92	0.1	0.56	-0.81	-0.62	-0.76	0.58	0.72
Pocfratio	-0.56	0.74	0.3	0.52	-0.13	0.1	-0.45	0.74	-0.56	0.04	0.62	0.43	-0.64	-0.42	0.42	0.23	0.58		0.78	0.0	1.0	-0.8	-0.57	-0.58	1.0	0.77
Interest Coverage	-0.88	0.94	0.36	0.9	-0.18	0.12	-0.28	0.94	-0.88	0.02	0.96	0.62	-0.86	-0.59	0.61	0.27	0.92	0.78		-0.09	0.77	-0.94	-0.53	-0.85	0.78	0.86
Capex To Operating Cash Flow	0.39	-0.31	-0.92	0.0	0.75	0.54	-0.71	-0.31	0.39	0.64	-0.09	-0.67	0.45	0.75	-0.77	-0.79	0.1	0.0	-0.09		-0.01	0.35	-0.35	0.48	0.0	-0.43
Pfcf Ratio	-0.55	0.73	0.31	0.5	-0.12	0.11	-0.44	0.73	-0.55	0.05	0.6	0.42	-0.63	-0.41	0.42	0.24	0.56	1.0	0.77	-0.01		-0.78	-0.57	-0.56	1.0	0.76
Days Payables Outstanding	0.95	-0.99	-0.6	-0.83	0.46	0.11	0.14	-0.99	0.95	0.22	-0.9	-0.81	0.96	0.79	-0.75	-0.43	-0.81	-0.8	-0.94	0.35	-0.78		0.37	0.95	-0.8	-0.98
Income Quality	0.21	-0.3	0.02	-0.48	-0.57	-0.86	0.12	-0.3	0.21	-0.81	-0.43	0.22	0.25	-0.19	-0.25	-0.25	-0.62	-0.57	-0.53	-0.35	-0.57	0.37		0.16	-0.57	-0.27
Roe	0.99	-0.97	-0.67	-0.84	0.63	0.27	0.0	-0.97	0.99	0.39	-0.89	-0.91	0.99	0.89	-0.79	-0.44	-0.76	-0.58	-0.85	0.48	-0.56	0.95	0.16		-0.58	-0.96
Ev To Operating Cash Flow	-0.57	0.75	0.3	0.52	-0.13	0.1	-0.45	0.75	-0.57	0.04	0.62	0.43	-0.64	-0.42	0.43	0.23	0.58	1.0	0.78	0.0	1.0	-0.8	-0.57	-0.58		0.77
Pe Ratio	-0.93	0.97	0.66	0.77	-0.59	-0.23	-0.11	0.97	-0.93	-0.34	0.84	0.87	-0.97	-0.85	0.76	0.45	0.72	0.77	0.86	-0.43	0.76	-0.98	-0.27	-0.96	0.77

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	31.61	41.83	28.75	18.91	21.74	20.66
Ptb Ratio	3.79	6.63	2.75	3.76	3.39	3.56
Book Value Per Share	16.36	9.58	9.09	6.77	6.09	5.25
Free Cash Flow Yield	0.0735	(0.0428)	(0.12)	(0.0924)	(0.11)	(0.1)
Operating Cash Flow Per Share	5.08	(2.69)	(2.84)	(1.76)	(2.03)	(1.92)
Stock Based Compensation To Revenue	0.15	0.34	0.76	0.55	0.49	0.35
Capex To Depreciation	5.16	0.67	0.95	9.67	8.7	9.14
Pb Ratio	3.79	6.63	2.75	3.76	3.39	3.56
Ev To Sales	31.22	41.42	27.66	18.59	21.37	20.3
Free Cash Flow Per Share	4.56	(2.72)	(2.89)	(2.35)	(2.71)	(2.57)
Roic	(0.12)	(0.19)	(0.29)	(0.33)	(0.3)	(0.32)
Net Income Per Share	(2.53)	(2.04)	(2.82)	(2.52)	(2.9)	(3.04)
Payables Turnover	14.22	0.6	0.69	26.73	24.05	25.26
Sales General And Administrative To Revenue	0.54	0.5	0.94	0.7	0.81	1.19
Research And Ddevelopement To Revenue	1.82	1.88	3.51	2.41	2.77	4.91
Capex To Revenue	0.27	0.0219	0.0606	0.44	0.39	0.41
Cash Per Share	17.07	9.22	7.55	6.42	5.78	5.77
Pocfratio	12.21	(23.63)	(8.79)	(14.45)	(13.01)	(12.36)
Interest Coverage	(402.64)	(574.46)	(916.23)	(844.54)	(760.09)	(798.09)
Capex To Operating Cash Flow	0.1	(0.0124)	(0.0185)	(0.34)	(0.39)	(0.37)
Pfcf Ratio	13.61	(23.34)	(8.63)	(10.82)	(9.74)	(9.25)
Days Payables Outstanding	25.67	609.86	531.5	13.66	15.71	14.92
Income Quality	(1.93)	1.29	0.99	0.7	0.63	0.66
Roe	(0.15)	(0.21)	(0.31)	(0.37)	(0.43)	(0.41)
Ev To Operating Cash Flow	12.06	(23.4)	(8.46)	(14.21)	(12.78)	(12.15)
Pe Ratio	(24.48)	(31.09)	(8.87)	(10.11)	(9.1)	(9.56)
Return On Tangible Assets	(0.0902)	(0.16)	(0.25)	(0.26)	(0.23)	(0.24)
Ev To Free Cash Flow	13.45	(23.11)	(8.31)	(10.64)	(9.57)	(9.1)
Earnings Yield	(0.0279)	(0.0409)	(0.0322)	(0.11)	(0.0989)	(0.12)
Net Debt To E B I T D A	0.3	0.31	0.34	0.18	0.2	0.19
Current Ratio	2.73	5.62	8.84	4.73	4.26	4.47
Tangible Book Value Per Share	16.36	9.58	9.09	6.77	6.09	5.25
Graham Number	30.54	20.98	23.99	19.58	17.62	13.85
Shareholders Equity Per Share	16.36	9.58	9.09	6.77	6.09	5.25
Debt To Equity	0.0634	0.0391	0.0354	0.21	0.19	0.2
Capex Per Share	0.52	0.0333	0.0526	0.59	0.53	0.56

Pair Trading with Kymera Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kymera Stock

0.8

JNJ

Johnson Johnson

Pair Corr

Moving against Kymera Stock

0.53	MLAB	Mesa Laboratories Earnings Call This Week	Pair Corr
0.37	XFOR	X4 Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.

The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Kymera Historical Financial Ratios

About Kymera Financial Ratios Analysis

Kymera Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Payables Turnover

Kymera Therapeutics fundamentals Correlations

Kymera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kymera Therapeutics fundamentals Accounts

Pair Trading with Kymera Therapeutics

Moving together with Kymera Stock

Moving against Kymera Stock

Additional Tools for Kymera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio
Roe	+ 0.99	Price To Sales Ratio

Days Payables Outstanding	- 0.99	Pb Ratio
Days Payables Outstanding	- 0.99	Ptb Ratio
Pe Ratio	- 0.98	Days Payables Outstanding
Days Of Inventory On Hand	- 0.98	Inventory Turnover
Pe Ratio	- 0.97	Net Income Per Share
Roe	- 0.97	Pb Ratio